GLOWseries of products Combined Peptides GHK-CU TB500 Sustainability Recyclable Vials High quality
TDS
12004-37-4
Pharmaceutical Grade
99.98%
Hong Kong
Customization Available
10 bottles per box
2026-09-12
Retatrutide,Tirzepatide,GLOW,KLOW80,NAD+,TB500
-
Product Description
-
Seller Information
-
History Price
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Aluminum strontium oxide (Al2SrO4)
Other Name:Aluminum strontium oxide (Al2SrO4);Aluminum strontium oxide (SrAl2O4);Aluminate (AlO21-),strontium (2:1);Strontium aluminate (SrAl2O4);Dialuminum strontium tetraoxide;N Luminous;G 201-60;160578-21-2
CAS No.:12004-37-4
Molecular Formula:Al.O.Sr
InChIKeys:InChIKey=JMSQRYPCBKBWLI-UHFFFAOYSA-N
Molecular Weight:205.58
Exact Mass:207.86400
EC Number:234-455-3
Categories:
Characteristics-
PSA:
52.60000
XLogP3:-0.14940
Appearance:-100 Mesh Powder
Density:3.20 g/cm3
Water Solubility:Slightly soluble in water.
Research-
Class:
Actin-sequestering protein / 43-amino-acid peptide
Status:Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)
Mechanism:A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.
Activity note:Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.
Source:Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI
Clinical Development:
References-
DrugBank:PubChem:UNII:Disclaimer:
Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Skin irritation, Category 2
Eye irritation, Category 2
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H315 Causes skin irritation
H319 Causes serious eye irritation
H335 May cause respiratory irritation
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P302+P352 IF ON SKIN: Wash with plenty of water/...
P321 Specific treatment (see ... on this label).
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,GLOW,KLOW80,NAD+,TB500
-
Location:
Room 11B, Building 0056, No. 81-1 Nonglinxia Road, Yuexiu District, Guangzhou City, Guangdong Province
-
Payment Terms:
100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Weekly Price
The chart shows the price trend of the product in the past 12 months.
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product